I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| ciliated cell | 17 studies | 38% ± 17% | |
| epithelial cell | 7 studies | 36% ± 16% | |
| basal cell | 5 studies | 26% ± 13% | |
| extravillous trophoblast | 3 studies | 33% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 17 studies | 38% ± 17% | |
| epithelial cell | 7 studies | 36% ± 16% | |
| basal cell | 5 studies | 26% ± 13% | |
| extravillous trophoblast | 3 studies | 33% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 2907.92 | 180 / 180 | 100% | 76.97 | 430 / 430 |
| prostate | 100% | 6725.41 | 245 / 245 | 100% | 193.45 | 502 / 502 |
| breast | 100% | 3216.66 | 459 / 459 | 100% | 187.64 | 1116 / 1118 |
| uterus | 100% | 2899.24 | 170 / 170 | 100% | 134.87 | 458 / 459 |
| bladder | 100% | 3906.24 | 21 / 21 | 100% | 95.03 | 502 / 504 |
| intestine | 100% | 3366.51 | 966 / 966 | 99% | 90.07 | 524 / 527 |
| lung | 99% | 3174.14 | 574 / 578 | 100% | 105.87 | 1152 / 1155 |
| skin | 100% | 4390.09 | 1809 / 1809 | 99% | 76.09 | 467 / 472 |
| thymus | 100% | 3668.65 | 653 / 653 | 99% | 65.67 | 597 / 605 |
| esophagus | 100% | 4441.28 | 1445 / 1445 | 98% | 75.83 | 180 / 183 |
| stomach | 100% | 3079.65 | 359 / 359 | 98% | 74.98 | 280 / 286 |
| pancreas | 100% | 2793.55 | 328 / 328 | 98% | 78.21 | 174 / 178 |
| kidney | 100% | 4452.36 | 89 / 89 | 95% | 97.86 | 860 / 901 |
| liver | 100% | 3673.56 | 226 / 226 | 91% | 54.21 | 371 / 406 |
| adrenal gland | 100% | 2784.88 | 258 / 258 | 51% | 20.22 | 118 / 230 |
| brain | 83% | 2316.33 | 2204 / 2642 | 60% | 23.16 | 424 / 705 |
| adipose | 100% | 2588.69 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 47.78 | 29 / 29 |
| spleen | 100% | 2188.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 127.03 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 78.17 | 1 / 1 |
| blood vessel | 100% | 2624.14 | 1331 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 99% | 1619.59 | 794 / 803 | 0% | 0 | 0 / 0 |
| heart | 96% | 1875.87 | 829 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 95% | 45.32 | 76 / 80 |
| peripheral blood | 52% | 1704.42 | 485 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0050848 | Biological process | regulation of calcium-mediated signaling |
| GO_0075509 | Biological process | endocytosis involved in viral entry into host cell |
| GO_0005829 | Cellular component | cytosol |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0005515 | Molecular function | protein binding |
| Gene name | JPT2 |
| Protein name | Jupiter microtubule associated homolog 2 (cDNA FLJ52046, moderately similar to Hematological and neurological expressed1-like protein) Jupiter microtubule associated homolog 2 (Hematological and neurological expressed 1-like protein) (HN1-like protein) Jupiter microtubule associated homolog 2 (cDNA FLJ50401, highly similar to Hematological and neurological expressed1-like protein) (cDNA, FLJ79413, highly similar to Hematological and neurological expressed 1-like protein) Jupiter microtubule associated homolog 2 |
| Synonyms | HN1L L11 C16orf34 |
| Description | FUNCTION: Nicotinic acid adenine dinucleotide phosphate (NAADP) binding protein required for NAADP-evoked intracellular calcium release . Confers NAADP-sensitivity to the two pore channels (TPCs) complex . Enables NAADP to activate Ca(2+) release from the endoplasmic reticulum through ryanodine receptors . .; FUNCTION: (Microbial infection) Involved in the endolysosomal trafficking of human coronavirus SARS-CoV-2. . |
| Accessions | ENST00000561516.5 H3BMT0 ENST00000382711.9 [Q9H910-2] ENST00000565851.5 H3BU16 Q9H910 ENST00000562569.1 ENST00000562684.5 [Q9H910-3] ENST00000248098.8 [Q9H910-1] H3BS08 H3BMV3 H3BTV5 H3BMM8 B4E1P3 ENST00000382710.8 ENST00000566742.5 ENST00000566925.5 A6NGP5 ENST00000566691.5 ENST00000569765.5 |
